Osteoporotic fractures are one of the principal adverse effects resulting from the therapeutic use of glucocorticoids. These fractures contribute substantially to morbidity in patients who already have major disabling chronic diseases. The prevention of these fractures is, therefore, a high priority in patients who require glucocorticoids, particularly older patients.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Compston, J. Management of glucocorticoid-induced osteoporosis. Nat. Rev. Rheumatol. 6, 82–88 (2010).
van Staa, T. P., Leufkens, H. G. M. & Cooper, C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13, 777–787 (2002).
Reid, D. M. et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J. Bone Miner. Res. 15, 1006–1013 (2000).
Axelsson, K. F., Nilsson, A. G., Wedel, H., Lundh, D. & Lorentzon, M. Association between alendronate use and hip fracture risk in older patients using oral prednisolone. JAMA 318, 146–155 (2017).
Saag, K. G. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028–2039 (2007).
Bone, H. G. et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96, 972–980 (2011).
Saag, K. G. et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(18)30075-5 (2018).
Murad, M. H. et al. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J. Clin. Endocrinol. Metab. 97, 1871–1880 (2012).
Popp, A. W., Zysset, P. K. & Lippuner, K. Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. Osteoporos Int. 27, 1917–1921 (2016).
Horne, A. M., Mihov, B. & Reid, I. R. Bone loss after romosozumab/denosumab: effects of bisphosphonates. Calcif. Tissue Int. https://doi.org/10.1007/s00223-018-0404-6 (2018).
Acknowledgements
I.R.R. receives research funding from the Health Research Council of New Zealand.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author’s institution has received research funding from Amgen, Merck and Novartis, and the author has received honoraria from these companies and from Eli Lilly.
Rights and permissions
About this article
Cite this article
Reid, I.R. Denosumab for glucocorticoid-induced osteoporosis. Nat Rev Endocrinol 14, 383–384 (2018). https://doi.org/10.1038/s41574-018-0035-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-018-0035-z